B P Imbimbo

Summary

Affiliation: Chiesi Farmaceutici
Country: Italy

Publications

  1. doi request reprint Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Via Palermo 26 A, Parma, Italy
    Expert Opin Investig Drugs 20:325-41. 2011
  2. ncbi request reprint Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide
    Nadia Moretto
    Department of Biochemistry and Molecular Biology, Chiesi Farmaceutici, University of Parma, 43100 Parma, Italy
    J Biol Chem 282:11436-45. 2007
  3. ncbi request reprint In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Via Palermo 26 A, 43100 Parma, Italy
    Pharmacol Res 55:318-28. 2007
  4. ncbi request reprint 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity
    Bruno P Imbimbo
    Research and Development, Chiesi Farmaceutici, Via Palermo 26 A, 43100 Parma, Italy
    J Pharmacol Exp Ther 323:822-30. 2007
  5. ncbi request reprint Therapeutic potential of gamma-secretase inhibitors and modulators
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    Curr Top Med Chem 8:54-61. 2008
  6. doi request reprint Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects
    Bruno P Imbimbo
    Research and Development, Chiesi Pharmaceuticals Inc, Rockville, MD, USA
    Alzheimer Dis Assoc Disord 27:278-86. 2013
  7. pmc Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
    Sandra Sivilia
    Department of Veterinary Medicine, University of Bologna, Bologna, Italy
    BMC Neurosci 14:44. 2013
  8. doi request reprint Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    Expert Rev Clin Immunol 8:135-49. 2012
  9. pmc CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease
    B P Imbimbo
    Research and Development, Chiesi Farmaceutici, Via Palermo, Parma, Italy
    Br J Pharmacol 156:982-93. 2009
  10. doi request reprint Why did tarenflurbil fail in Alzheimer's disease?
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    J Alzheimers Dis 17:757-60. 2009

Collaborators

Detail Information

Publications22

  1. doi request reprint Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Via Palermo 26 A, Parma, Italy
    Expert Opin Investig Drugs 20:325-41. 2011
    ..Compounds that inhibit or modulate γ-secretase, the pivotal enzyme which generates β-amyloid (Aβ), are potential therapeutics for Alzheimer's disease (AD)...
  2. ncbi request reprint Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide
    Nadia Moretto
    Department of Biochemistry and Molecular Biology, Chiesi Farmaceutici, University of Parma, 43100 Parma, Italy
    J Biol Chem 282:11436-45. 2007
    ..The data indicate that a conformational epitope shared by oligomers and fibrils can be mimicked by a thioredoxin-constrained Abeta fragment repeat and identify Trx(Abeta15)4 as a promising new tool for AD immunotherapy...
  3. ncbi request reprint In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Via Palermo 26 A, 43100 Parma, Italy
    Pharmacol Res 55:318-28. 2007
    ..105) with CHF5022 concentration in the brain. CHF5022 and CHF5074 thus appear to have a promising in vitro and in vivo profile. This warrants further evaluation of their long-term effects on Abeta brain pathology...
  4. ncbi request reprint 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity
    Bruno P Imbimbo
    Research and Development, Chiesi Farmaceutici, Via Palermo 26 A, 43100 Parma, Italy
    J Pharmacol Exp Ther 323:822-30. 2007
    ..CHF5074 is therefore a promising therapeutic agent for Alzheimer's disease...
  5. ncbi request reprint Therapeutic potential of gamma-secretase inhibitors and modulators
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    Curr Top Med Chem 8:54-61. 2008
    ..A large ongoing Phase 3 study with (R)-flurbiprofen, a claimed selective Abeta42 lowering agent, will tell us if allosteric modulation of gamma-secretase is clinically effective...
  6. doi request reprint Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects
    Bruno P Imbimbo
    Research and Development, Chiesi Pharmaceuticals Inc, Rockville, MD, USA
    Alzheimer Dis Assoc Disord 27:278-86. 2013
    ..Drug levels in the CSF were dose-proportional. The drug dose-dependently lowered the levels of the soluble CD40 ligand, a marker of microglia activation, in both plasma and CSF samples...
  7. pmc Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
    Sandra Sivilia
    Department of Veterinary Medicine, University of Bologna, Bologna, Italy
    BMC Neurosci 14:44. 2013
    ....
  8. doi request reprint Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    Expert Rev Clin Immunol 8:135-49. 2012
    ....
  9. pmc CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease
    B P Imbimbo
    Research and Development, Chiesi Farmaceutici, Via Palermo, Parma, Italy
    Br J Pharmacol 156:982-93. 2009
    ....
  10. doi request reprint Why did tarenflurbil fail in Alzheimer's disease?
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    J Alzheimers Dis 17:757-60. 2009
    ..In addition, based on previous negative results with several anti-inflammatory drugs in AD, it is hypothesized that the residual anti-inflammatory activity of tarenflurbil may have a detrimental effect on disease progression...
  11. ncbi request reprint Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease
    Bruno P Imbimbo
    Chiesi Farmaceutici SpA, Research and Development Department, Via Palermo 26 A, 43100 Parma, Italy
    Curr Opin Investig Drugs 10:721-30. 2009
    ..Semagacestat is the most advanced gamma-secretase inhibitor and represents a major hope among therapies designed to slow the rate of cognitive decline of patients with AD...
  12. doi request reprint An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Via Palermo 26 A, 43100 Parma, Italy
    Expert Opin Investig Drugs 18:1147-68. 2009
    ....
  13. ncbi request reprint γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Via Palermo 26 A, 43100 Parma, Italy
    Curr Top Med Chem 11:1555-70. 2011
    ..New Notch-sparing γ-secretase inhibitors and more potent, more brain penetrant γ-secretase modulators are being developed with the hope of overcoming the previous setbacks...
  14. ncbi request reprint Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
    B P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    CNS Drugs 15:375-90. 2001
    ..Other contributing pharmacodynamic factors are the rate of onset of and fluctuations in acetylcholinesterase inhibition at steady state...
  15. ncbi request reprint The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease
    Bruno P Imbimbo
    Chiesi Farmaceutici, Research and Development Department, Via Palermo 26 A, 43100 Parma, Italy
    Expert Opin Investig Drugs 13:1469-81. 2004
    ..Thus, new NSAID analogues are being developed with potent and selective inhibitory activity on Abeta42 but with either lack of COX inhibitory activity or reduced gastrointestinal toxicity potential...
  16. ncbi request reprint Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion
    Ilaria Peretto
    Research and Development, Chiesi Farmaceutici s p a, Via Palermo 26 A, 43100 Parma, Italy
    J Med Chem 48:5705-20. 2005
    ..Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma Abeta42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD...
  17. doi request reprint CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease
    Bruno P Imbimbo
    Research and Development, Chiesi Farmaceutici, Parma, Italy
    J Alzheimers Dis 20:159-73. 2010
    ..040). These effects were associated to a complete reversal of contextual memory deficit (p=0.006). Contextual memory significantly correlated with synaptophysin immunoreactivity in the cortex (r=0.548, p=0.0038)...
  18. ncbi request reprint Pathophysiology of Alzheimer's disease
    Bruno P Imbimbo
    Research and Development Department, Chiesi Farmaceutici, Parma, Italy
    Neuroimaging Clin N Am 15:727-53, ix. 2005
    ..Progress is needed in understanding the mechanisms that link beta-amyloid accumulation and neuronal death. The next 5 years will be crucial in this respect...
  19. pmc Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects
    Beatrice Astruc
    Biotrial, 7 9 rue Jean Louis Bertrand, 35000 Rennes, France
    Br J Clin Pharmacol 59:405-14. 2005
    ..To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CHF3381, a dual NMDA and MAO-A inhibitor, after multiple oral doses in healthy subjects...
  20. ncbi request reprint High throughput screening of beta-amyloid secretion inhibitors using homogenous time-resolved fluorescence
    Hugo Albrecht
    Discovery Partners International, Integrated Drug Discovery Division, Allschwil, Switzerland
    Comb Chem High Throughput Screen 7:745-56. 2004
    ..7 were achieved in a 384-well format. High throughput screening of 56,913 potential Abeta production inhibitors led to identification of new non-cytotoxic and cell permeable compounds with potencies in the submicromolar range...
  21. ncbi request reprint Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects
    Antoine Tarral
    Biotrial, Technopole Atalante Villejean, Rennes, France
    J Clin Pharmacol 43:901-11. 2003
    ..The ingestion of food seems to not affect the extent of absorption of the drug. Minor effects on the central nervous system were detected at doses equal to or greater than 300 mg...
  22. ncbi request reprint Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1)
    Ilaria Peretto
    NiKem Research, Via Zambeletti 25, 20021 Baranzate, Milan, Italy
    J Med Chem 50:1571-83. 2007
    ..8 nM and for M2 receptor Ki = 1141 nM. Functional in vitro studies on selected compounds confirmed the antagonist activity toward the M3 receptor and functional selectivity toward the M2 receptor...